22
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Chronic myelogenous leukemia

Curable with early diagnosis and treatment

, MD & , MD
Pages 149-159 | Published online: 30 Jun 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Elias Jabbour, Samih El Ahdab, Jorge Cortes & Hagop Kantarjian. (2008) Nilotinib: a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of leukemias. Expert Opinion on Investigational Drugs 17:7, pages 1127-1136.
Read now

Articles from other publishers (5)

Ivana Drobnjak & A. C. Fowler. (2011) A Model of Oscillatory Blood Cell Counts in Chronic Myelogenous Leukaemia. Bulletin of Mathematical Biology 73:12, pages 2983-3007.
Crossref
Dong-Wook Kim, Shripad D. Banavali, Udomsak Bunworasate, Yeow-Tee Goh, Peter Ganly, He Huang, Ian Irving, Saengsuree Jootar, Hyun-Gyung Goh, Liang-Piu Koh, Wei Li, Tomoki Naoe, Soo-Chin Ng, Visalachy Purushotaman, Harryanto Reksodiputro, Lee-Yung Shih, Jih-Luh Tang, Arinobu Tojo, Jianmin Wang & Raymond Wong. (2010) Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era. Leukemia Research 34:11, pages 1459-1471.
Crossref
Elias Jabbour, Carmen Fava & Hagop Kantarjian. (2009) Advances in the biology and therapy of patients with chronic myeloid leukaemia. Best Practice & Research Clinical Haematology 22:3, pages 395-407.
Crossref
Elias Jabbour, Jorge Cortes, Francis Giles, Susan O’Brien & Hagop Kantarjian. (2006) The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. Targeted Oncology 1:4, pages 186-196.
Crossref
Kathleen M. Duffy. (2003) Innovations in the Management of Leukemia. Cancer Nursing 26:Supplement 6S, pages 26S???31S.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.